Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3432556 | 0.83 | KDM4E (0.52) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL29518275 | 0.82 | HIF1A (0.48) | PDE4APDE4BPDE4CPDE4DNAPRT | |
| SCHEMBL3594386 | 0.82 | SLC22A12 (0.46) | PDE4APDE4BPDE4CPDE4DNAPRT | |
| SCHEMBL24368588 | 0.82 | THRB (0.45) | PDE4APDE4BPDE4CPDE4DNAPRT | |
| SCHEMBL29518290 | 0.82 | THRB (0.45) | PDE4APDE4BPDE4CPDE4DNAPRT | |
| SCHEMBL24368236 | 0.82 | HIF1A (0.48) | PDE4APDE4BPDE4CPDE4DNAPRT | |
| SCHEMBL29518155 | 0.81 | RXRA (0.43) | PDE4APDE4BPDE4CPDE4DNAPRT | |
| SCHEMBL24368262 | 0.81 | RXRA (0.43) | PDE4APDE4BPDE4CPDE4DNAPRT | |
| SCHEMBL3586120 | 0.80 | PDE4A (0.39) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL24368303 | 0.78 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DNAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081937-B1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2081937-B1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8071581-B2 | Triazolopyridazine protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071581-B2 | Triazolopyridazine protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071581-B2 | Triazolopyridazine protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| EP-2081937-A2 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008051805-A2 | TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051805-A2 | TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | MAP4K5, MAPKAPK5, MAP4K2 | PDE4A 337/4885PDE4B 492/4885PDE4C 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.